Sansure Biotech(SH:688289) Sou Hu Cai Jing·2025-08-08 11:21Financial Performance - As of the first quarter of 2025, the company reported total revenue of 475 million yuan, representing a year-on-year growth of 21.62% [1] - The net profit attributable to shareholders was 91.73 million yuan, an increase of 13.22% year-on-year [1] - The non-recurring net profit was 90.50 million yuan, showing a year-on-year growth of 22.70% [1] - The current ratio stood at 4.439, and the quick ratio was 4.159, indicating strong liquidity [1] - The debt-to-asset ratio was 23.25%, reflecting a low level of financial leverage [1] Stock Performance - As of August 8, 2025, the stock price closed at 21.78 yuan, down 1.94% [1] - The turnover rate was 1.73%, with a trading volume of 100,300 lots and a transaction amount of 221 million yuan [1] - There was a net outflow of main funds amounting to 15.86 million yuan, accounting for 7.19% of the transaction amount [1] Investment and Intellectual Property - The company has made investments in 27 enterprises and participated in 1,054 bidding projects [2] - It holds 387 trademark registrations and 467 patent applications, indicating a strong focus on intellectual property [2] - The company has obtained 311 administrative licenses, showcasing its compliance and operational capabilities [2] Company Overview - Established in 2008, the company is located in Changsha and primarily engages in the pharmaceutical manufacturing industry [1] - The registered capital is approximately 5.79 billion yuan, with paid-in capital of about 1.26 billion yuan [1] - The legal representative of the company is Dai Lizhong [1]